14 February 2013Patents

Bristol-Myers Squibb loses Baraclude patent fight with Teva

A US judge has invalidated pharmaceutical company Bristol-Myers Squibb (BMS)’s patent covering its hepatitis B treatment Baraclude, agreeing with generic manufacturer Teva Pharmaceuticals that the invention of the active compound in the drug was obvious to anyone skilled in medicinal chemistry.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

Tesla ‘Robotaxi’ and ‘Cybercab’ TMs rebuffed by USPTO on eve of launch

UK-India trade deal is ‘missed opportunity’, say industry bodies

AI, lipstick deals and mental health: What’s on CITMA president’s radar?

WATCH: Recent developments in design patent law

SEPs now searchable on WIPO’s global patent database

INTA 2025: San Diego to host largest post-COVID Annual Meeting

'Nothing can stand in the way of our work': Ukraine resumes IP system

Foley adds five-partner team from Perkins Coie and K&L Gates

Bristol-Myers Squibb loses Baraclude patent fight with Teva

Editor's picks

Editor's picks

More articles